Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.
Hosted on MSN
Stopping DNA damage in T cells during PARP inhibitor cancer treatment enhances antitumor effectiveness
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...
Niraparib combined with abiraterone acetate and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially BRCA1/2 mutations. The combination showed potential in reducing ...
The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson & Johnson’s Akeega is giving the class a win in ...
Eisbach Bio plans to use a $4.75m grant to advance EIS-12656, a small molecule ALC1 inhibitor to disrupt the genome structure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback